Literature DB >> 18606086

Neuro-ophthalmic complications in giant cell arteritis.

Frances A Borg1, Victoria L J Salter, Bhaskar Dasgupta.   

Abstract

Giant cell arteritis (GCA) is a medical emergency characterized by systemic inflammation and critical ischemia. Neuro-ophthalmic complications occur early, with permanent vision loss in up to one fifth of patients. This mainly results from failure of prompt recognition and treatment. Diagnosis of GCA is often preceded by unrecognized symptoms, including constitutional upset and jaw claudication. Features predictive of permanent visual loss include jaw claudication and temporal artery abnormalities on physical examination. These patients often do not mount high inflammatory responses. Modern imaging techniques show diagnostic promise, and have led to an increased recognition of major artery involvement in GCA. However, temporal artery biopsy remains the gold standard for investigation. Intimal hyperplasia on histologic examination is associated with neuro-ophthalmic complications. The mainstay of therapy remains corticosteroids. Experience using conventional disease-modifying drugs has been mixed, and biologic therapies require further evaluation for their steroid-sparing potential.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606086     DOI: 10.1007/s11882-008-0052-4

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  54 in total

1.  Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis.

Authors:  Carlo Salvarani; Luca Cimino; Pierluigi Macchioni; Dario Consonni; Fabrizio Cantini; Gianluigi Bajocchi; Nicolò Pipitone; Maria Grazia Catanoso; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2005-04-15

2.  Slowly progressive vision loss in giant cell arteritis.

Authors:  Anat Galor; Michael S Lee
Journal:  Arch Ophthalmol       Date:  2006-03

Review 3.  Does this patient have temporal arteritis?

Authors:  Gerald W Smetana; Robert H Shmerling
Journal:  JAMA       Date:  2002-01-02       Impact factor: 56.272

4.  Orbital presentations of giant cell arteritis.

Authors:  A G Lee; R A Tang; S E Feldon; M Pless; J S Schiffman; R M Rubin; N Rao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-07       Impact factor: 3.117

5.  Disease patterns and tissue cytokine profiles in giant cell arteritis.

Authors:  C M Weyand; N Tetzlaff; J Björnsson; A Brack; B Younge; J J Goronzy
Journal:  Arthritis Rheum       Date:  1997-01

6.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.

Authors:  J Hernández-Rodríguez; M Segarra; C Vilardell; M Sánchez; A García-Martínez; M J Esteban; C Queralt; J M Grau; A Urbano-Márquez; A Palacín; D Colomer; M C Cid
Journal:  Rheumatology (Oxford)       Date:  2003-12-16       Impact factor: 7.580

7.  Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis.

Authors:  O Rauzy; M Fort; F Nourhashemi; L Alric; H Juchet; M Ecoiffier; M Abbal; D Adoue
Journal:  Ann Rheum Dis       Date:  1998-06       Impact factor: 19.103

8.  Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.

Authors:  José Hernández-Rodríguez; Marta Segarra; Carme Vilardell; Montse Sánchez; Ana García-Martínez; María-José Esteban; Josep M Grau; Alvaro Urbano-Márquez; Dolors Colomer; Hynda K Kleinman; Maria C Cid
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

9.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.

Authors:  Daniël Blockmans; Liesbet de Ceuninck; Steven Vanderschueren; Daniël Knockaert; Luc Mortelmans; Herman Bobbaers
Journal:  Arthritis Rheum       Date:  2006-02-15

Review 10.  Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature.

Authors:  Sohan Singh Hayreh; Bridget Zimmerman; Randy H Kardon
Journal:  Acta Ophthalmol Scand       Date:  2002-08
View more
  10 in total

1.  Delays in recognition and management of giant cell arteritis: results from a retrospective audit.

Authors:  Amara N Ezeonyeji; Frances A Borg; Bhaskar Dasgupta
Journal:  Clin Rheumatol       Date:  2010-11-18       Impact factor: 2.980

2.  Ophthalmic presentation of giant cell arteritis in African-Americans.

Authors:  S T Garrity; M Pistilli; M S Vaphiades; N Q Richards; P S Subramanian; P R Rosa; B L Lam; B J Osborne; G T Liu; K E Duncan; R K Shin; N J Volpe; K S Shindler; M S Lee; M L Moster; E H Tracey; S E Cuprill-Nilson; M A Tamhankar
Journal:  Eye (Lond)       Date:  2016-09-16       Impact factor: 3.775

Review 3.  Giant cell arteritis: ophthalmic manifestations of a systemic disease.

Authors:  Elisabeth De Smit; Eoin O'Sullivan; David A Mackey; Alex W Hewitt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-05       Impact factor: 3.117

Review 4.  Giant cell arteritis: a review.

Authors:  Pravin Patil; Niral Karia; Shaifali Jain; Bhaskar Dasgupta
Journal:  Eye Brain       Date:  2013-03-09

Review 5.  Giant Cell Arteritis: Beyond Corticosteroids.

Authors:  Lauren Steel; Asad Khan; Bhaskar Dasgupta
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

6.  Central Retinal Artery Occlusion: Acute Management and Treatment.

Authors:  Nitish Mehta; Rosa Dolz Marco; Raquel Goldhardt; Yasha Modi
Journal:  Curr Ophthalmol Rep       Date:  2017-04-18

7.  Design of the tocilizumab in giant cell arteritis trial.

Authors:  Sebastian H Unizony; Bhaskar Dasgupta; Elena Fisheleva; Lucy Rowell; Georg Schett; Robert Spiera; Jochen Zwerina; Olivier Harari; John H Stone
Journal:  Int J Rheumatol       Date:  2013-04-07

8.  Branch facial nerve trauma after superficial temporal artery biopsy: a case report.

Authors:  Richard A Rison
Journal:  J Med Case Rep       Date:  2011-01-26

9.  Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?

Authors:  Nicola Goodfellow; Julien Morlet; Surjeet Singh; Afsie Sabokbar; Andrew Hutchings; Vanshika Sharma; Jana Vaskova; Shauna Masters; Allahdad Zarei; Raashid Luqmani
Journal:  RMD Open       Date:  2017-03-29

10.  The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population.

Authors:  Max Yates; Karly Graham; Richard Arthur Watts; Alexander James MacGregor
Journal:  BMC Musculoskelet Disord       Date:  2016-07-15       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.